Intelligence

#Biotech #Financing #mRNA #Seed funding

Biotech raises a €31.5m seed round to develop mRNA therapeutics

SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.   The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More

#Business & Investment #News #Start-up Zone

Financing or funding
#Arthritis #Financing #Investment #Rheumatology #Spinout

Anaheim Bio launches with €40 million Series A financing

Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing.  The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta’s former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV… Read More

#Business & Investment #News #Start-up Zone

#ALLOX #Artificial intelligence (AI) #Drug discovery #Financing #Seed funding

ALLOX closes $10.5m financing to scale allosteric discovery platform

ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.   The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC… Read More

#Business & Investment #News #Start-up Zone

#Flagship Pioneering #Foundational model #Start-ups #Transcriptomics

New company Etcelera unites three drug discovery platforms

Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics.  The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More

#Business & Investment #News #Start-up Zone